Joan B. Heijns

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 335 citations · Full text

Medicine, Nutritional Sciences, Oncology +17

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Nature · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16